Trials / Completed

CompletedNCT00738257

A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.

A 2 Year Prospective, Multicentre, Open-label, Randomised, Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients (With a PTH > 150pg/ml) on a Ciclosporin A and Glucocorticoid Based Immunosuppressive Regimen.

Status: Completed
Phase: Phase 4
Study type: Interventional
Enrollment: 126 (actual)

Sponsor: Novartis Pharmaceuticals · Industry
Sex: All
Age: 18 Years – 75 Years
Healthy volunteers: Not accepted

Summary

The purpose of the study was to evaluate the effect of Pamidronate on bone mineral density loss and fracture rates up to 2 years, in post renal-transplant subjects on a Ciclosporin A and glucocorticoid based immunosuppressive regimen.

Conditions

Bone Loss

Interventions

Type	Name	Description
DRUG	Pamidronate

Timeline

Start date: 2000-06-01
Primary completion: 2004-12-01
First posted: 2008-08-20
Last updated: 2010-05-17

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT00738257. Inclusion in this directory is not an endorsement.